Michael Schmidt

Michael Schmidt

Company: Ankyra Therapeutics

Job title: Chief Scientific Officer

Seminars:

Group Panel Discussion: Side Effects – Mitigating Against Hypotension + Fever With Immune-Stimulating Agents (NK Cell Engagers, PD-1s, Cytokines, T-Cell Engagers) = Cytokine Release Syndrome (CRS)? 11:30 am

What are the differences between the symtoms and the tests Uncover the implications for patients and regulatory bodies Examine the Implications for CAR-T Could this redefine CRS?Read more

day: Day Two

Intratumoral Immunotherapy With Aluminum HydroxideTethered Cytokines 10:00 am

Discover how Ankyra’s platform improves the therapeutic window of cytokine drugs by increasing local retention following intratumoral administration Analyze how cytokines are stably complexed with the common vaccine adjuvant aluminum hydroxide through fusion to a proprietary alum binding peptide Visualise cytokine-alum complexes forming a stable depot in the tumor leading to prolonged immune activation and…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.